Realtime Oncology is a subsidiary of Oncompass Medicine. Oncompass Medicine is one of the leading providers of precision oncology services since 2003.
2003 – Our founder physicians were among the first to treat an EGFR mutant lung cancer patient prospectively based on the molecular evidence, which was published in Journal of Clinical Oncology in 2005.
2008 – We were among the first to use next generation sequencing (NGS) in precision oncology in the world.
2008 – Our scientists published evidence for EGFR mutations as independent predictive biomarkers.
2010 – Our scientists published their invited review on precision oncology and drug discovery in Nature Reviews Drug Discovery.
2016 – Oncompass Medicine introduced the Realtime Oncology Treatment Calculator™ at the 10th Personalized Medicine World Conference, in Mountain View, California
2017 – We became the partner of the National Oncogenomics and Precision Oncotherapy Program in Hungary
2018 – We are opening up our Realtime Oncology Treatment Calculator™ to every interested party.
We have always been in the forefront of precision oncology, and we believe that rule-based artificial intelligence is the next logical step in precision oncology to translate the results of molecular profiling, functional annotations and knowledge bases into clinical decisions. With having this in our mind, we have developed the Molecular Treatment Calculator to offer a standardised, objective and transparent method for ranking available targeted therapy options. Simple molecular reports are the past, a complex decision support engine is the future.
We think of our teamwork as a rafting place in oncology. If you like to take challenges and rough pathways, and would like to join us or learn more about our solutions, please contact us.